Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Breast Cancer Therapeutics Market Analysis 2016 - Forecast to 2022 - Research and Markets

Research and Markets
Posted on: 20 Sep 16

Research and Markets has announced the addition of the "Global Breast Cancer Therapeutics Market Analysis 2016 - Forecast to 2022" report to their offering.

This report analyzes the global markets for "Breast Cancer Therapeutics". The market assessment is performed through standard and the tailored research methodology approach.

Annual estimations and forecasts are provided from the year 2013 to 2022 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends.

Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities.

This report provides:

  • Market Sizing estimations and forecasts for a minimum of 6 years of all the given segments, sub segments and the regional markets
  • Identifying market dynamics (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Regional and country level market analysis
  • Competitive landscaping mapping the key common trends
  • Company profiling covering the financials, recent activities and the future strategies
  • Supply chain trends mapping the recent advancements
  • Strategic recommendations for the new entrants

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Market Analysis

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Breast Cancer Therapeutics Market by Drug Class

5.1 Introduction

5.2 Hormone Receptor

5.3 Mitotic Inhibitors

5.4 HER2 Inhibitors

5.5 Anti-metabolites

5.6 Aromatase Inhibitors

6 Geographical Segmentation

7 Vendor Landscaping

7.1 Agreements, Partnerships, Collaborations and Joint Ventures

7.2 Acquisitions & Mergers

7.3 New Product Launch

7.4 Expansions

7.5 Other Key Strategies

8 Company Profiles

  • Novartis
  • AstraZeneca
  • Galena Biopharma
  • BioMarin
  • OBI Pharma
  • Oncothyreon
  • Pfizer
  • CTI BioPharma
  • Bayer HealthCare
  • Genentech
  • AbbVie
  • Array BioPharma
  • Eli Lily
  • Oryzon
  • Celgene
  • Puma Biotechnology
  • Bristol-Myers Squibb
  • Eisai
  • Color Genomics
  • Merck
  • Takeda
  • Halozyme Therapeutics
  • Tracon
  • Syndax
  • Janssen Biotech
  • Tesaro
  • Santen Pharma
  • MacroGenics
  • Servier
  • Roche
  • Lycera
  • ImmunoGen
  • Sprint Bioscience

For more information about this report visit

Related Topics: Women's Health, Breast Cancer Drugs

View source version on

Business Wire

Last updated on: 20/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.